Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population

Genetic Testing and Molecular Biomarkers

Volumn 21, Issue 5, 2017, Pages 298-304

  Afilal, Driss ^a   Basselam, Mohamed Amine ^a   Brakez, Zahra ^a   Chouham, Said ^a   Brehm, António ^b   Izaabel, El Hassan ^a  

^a FACULTÉ DES SCIENCES   (Morocco)

^b UNIVERSITY OF MADEIRA   (Portugal)

Author keywords

CYP2C9 and CYP2C19 genes; drug metabolism; individual and interethnic variability; poor metabolizer (PM) phenotype; South Moroccan population

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INTRON; METABOLIC DISORDER; MOLECULAR TYPING; MOROCCAN; NORMAL HUMAN; NULL ALLELE; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION SITE; ADULT; FEMALE; GENETICS; MALE; METABOLISM; MOROCCO; MUTATION; POPULATION GENETICS; YOUNG ADULT;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MOROCCO; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 85019171686     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2016.0304     Document Type: Article

References (65)

1. Allabi AC, Gala JL, Desager JP, et al. (2003) Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56:653-657.
2. Alzahrani AM, Ragia G, Hanieh H, et al. (2013) Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. Biomed Res Int 2013:315980.
3. Arvanitidis K, Ragia G, Iordanidou M, et al. (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419-426.
4. Aynacioglu AS, Sachse C, Bozkurt A, et al. (1999a) Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther 66:185-192.
5. Aynacioglu S, Brockmöller J, Bauer S, et al. (1999b) Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 48:409-415.
6. Bathum L, Skjelbo E, Mutabingwa TK, et al. (1999) Pheno-types and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 48:395-401.
7. Baumann P, Rougemont M, Corruble E, et al. (2013) Recommendations pour le monitoring plasmatique des médi-camnets antidépresseurs. Acta Psychiatr Belg 9:577-586.
8. Bozina N, Bradamante V, Lovrić M (2009) Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 60:217-242.
9. Budi T, Tóth K, Nagy A, et al. (2015) Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia 56:849-855.
10. Burian M, Grösch S, Tegeder I, et al. (2002) Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 54:518-521.
11. Carbonell N, Verstuyft C, Massard J, et al. (2010) CYP2C9∗ 3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin. Clin Pharmacol Ther 87:693-698.
12. Dandara C, Lombard Z, Du Plooy I, et al. (2011) Genetic variants in CYP (-1A2,-2C9,-2C19,-3A4 and-3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 12:1663-1670.
13. De Morais S, Wilkinson GR, Blaisdell J, et al. (1994a) Identi-fication of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598.
14. De Morais S, Wilkinson GR, Blaisdell J, et al. (1994b) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422.
15. Desta Z, Zhao X, Shin J-G, et al. (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958.
16. Djaffar-Jureidini I, Chamseddine N, Keleshian S, et al. (2011) Pharmacogenetics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population. Genet Test Mol Biomarkers 15:827-830.
17. Excoffier L, Lischer HE (2010) Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 10:564-567.
18. Ferguson RJ, De Morais SM, Benhamou S, et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
19. Fukasawa T, Suzuki A, Otani K (2007) Effects of genetic poly-morphism of cytochrome P450 enzymes on the pharmaco-kinetics of benzodiazepines. J Clin Pharm Ther 32:333-341.
20. Garćia-Martin E, Martinez C, Ladero JM, et al. (2006) Inter-ethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 10: 29-40.
21. Gidal BE (2015) Phenytoin hypersensitivity: it's time for some individuality. Epilepsy Curr 15:177-179.
22. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355.
23. Goldstein JA, de Morais SM (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacoge-netics 4:285-299.
24. Goldstein JA, Ishizaki T, Chiba K, et al. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephe-nytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
25. Gray IC, Nobile C, Muresu R, et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 28:328-332.
26. Hamdy SI, Hiratsuka M, Narahara K, et al. (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine de-hydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596-603.
27. Hirota T, Eguchi S, Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 28:28-37.
28. Ibeanu GC, Goldstein JA, Meyer U, et al. (1998) Identification of new human CYP2C19 alleles (CYP2C19∗ 6 and CYP2C19∗ 2B) in a Caucasian poor metabolizer of mephe-nytoin. J Pharmacol Exp Ther 286:1490-1495.
29. Ingelman-Sundberg M (2004) Human drug metabolising cyto-chrome P450 enzymes: properties and polymorphisms. Nau-nyn Schmiedebergs Arch Pharmacol 369:89-104.
30. Jonas DE, McLeod HL (2009) Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci 30:375-386.
31. Jureidini ID, Chamseddine N, Keleshian S, et al. (2011) Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 38:5449-5452.
32. Kimura M, Ieiri I, Mamiya K, et al. (1998) Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20:243-247.
33. Kirchheiner J, Brockmöller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1-16.
34. Klose TS, Blaisdell JA, Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295.
35. Kudzi W, Dodoo AN, Mills JJ (2009) Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 10:124.
36. Martis S, Peter I, Hulot J-S, et al. (2013) Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplo-types. Pharmacogenomics J 13:369-377.
37. Masimirembwa C, Bertilsson L, Johansson I, et al. (1995) Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656-661.
38. Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
39. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
40. Morais SM, Goldstein JA, Xie HG, et al. (1995) Genetic analysis of the S-mephenytoin polymorphism in a chinese population. Clin Pharmacol Ther 58:404-411.
41. Oliveira E, Marsh S, Van Booven D, et al. (2007) Pharmaco-genetically relevant polymorphisms in Portugal. Pharmaco-genomics 8:703-712.
42. Perry E (2011) Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms. Am J Health Syst Pharm 68:529-532.
43. Persson I, Aklillu E, Rodrigues F, et al. (1996) S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenet 6:521-526.
44. Pinto N, Dolan ME (2011) Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab 12:487-497.
45. Rettie AE, Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494.
46. Rollason V, Flora Samer C, Daali Y, et al. (2014) Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti-inflammatory drugs: a review. Curr Drug Metab 15:326-343.
47. Rosemary J, Adithan C (2007) The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2:93-109.
48. Sameer A-EI, Amany GM, Abdela AA, et al. (2009) CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can J Clin Pharmacol 16:156-162.
49. Scordo MG, Aklillu E, Yasar U, et al. (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450.
50. Scordo MG, Caputi AP, D'Arrigo C, et al. (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195-200.
51. Scott SA, Khasawneh R, Peter I, et al. (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11:781-791.
52. Simon T (2013) Pharmacogénétique des antiagrégants pla-quettaires. La Lettre du Pharmacologue 27:76-79.
53. Sipeky C, Lakner L, Szabo M, et al. (2009) Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic fre-quencies. Blood Cells Mol Dis 43:239-242.
54. Takahashi H, Wilkinson GR, Caraco Y, et al. (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 73:253-263.
55. Tamminga W, Wemer J, Oosterhuis B, et al. (2001) The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 57:717-722.
56. Ucar M, Alagozlu H, Sahin S, et al. (2013) The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Med Glas 10:50-54.
57. Vicente J, González-Andrade F, Soriano A, et al. (2014) Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study. Mol Biol Rep 41:1267-1272.
58. Wang S-L, Huang J-d, Lai M-D, et al. (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42.
59. Xie H-G, Prasad HC, Kim RB, et al. (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257-1270.
60. Xie H-G, Stein CM, Kim RB, et al. (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539-549.
61. Yang JQ, Morin S, Verstuyft C, et al. (2003) Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 17:373-376.
62. Yasar U, Eliasson E, Dahl M-L, et al. (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant al-leles in a Swedish population. Biochem Biophys Res Com-mun 254:628-631.
63. Yousef A-M, Bulatova NR, Newman W, et al. (2012) Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep 39:9423-9433.
64. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes indrug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.
65. Zanger UM, Turpeinen M, Klein K, et al. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392: 1093-1108.